Tag: biologics

Future Biosimilars: Upcoming Patent Expirations and Market Entry

Upcoming patent expirations for blockbuster biologics like Keytruda and Eylea are set to unleash a wave of biosimilars, potentially saving the U.S. healthcare system hundreds of billions. Here’s what’s coming, who’s entering the market, and how it will change patient access.

learn more